CDH1 and colorectal carcinoma: In addition, the in vitro and in vivo experiments showed that low DDX3 expression promoted CRC progression by regulating E-cadherin and β-catenin signals by activating the MAPK pathway, while the PD98059 MEK inhibitor partially inhibited the proliferation and invasion of CRC cells, suggesting that targeting the MAPK pathway may be a therapeutic approach for advanced CRC.